Simvastatin, a once-patent-protected drug, has become a globally recognized pharmaceutical product with annual sales reaching $7 billion. Its patent expiration triggered the first wave of generic competition in the U.S. market, significantly impacting the financial results of major pharmaceutical companies. Teva saw a 87% increase in North American revenue and a 127% rise in net profit. Similarly, Ranbaxy reported a staggering 651% year-over-year growth in net profit, while Reddy’s profits surged by over 300%. Meanwhile, Merck, the original developer, faced a major setback, with its profits declining by 34% year-on-year.
Galaxy Securities noted that the initial phase of generic competition for simvastatin is nearing completion, and the industry's restructuring is becoming evident as some companies benefit more than others. As the global supply chain for simvastatin raw materials and finished products enters a new phase of competition after December, domestic manufacturers are expected to leverage their scale and cost advantages more effectively.
Hisun Pharmaceutical is well-positioned to gain from the next round of competition in the simvastatin market, which could mark a significant turning point in its performance. Analysts predict that the market price of simvastatin will fluctuate considerably between 2006 and 2007, and any potential price increases could have a substantial impact on the profitability of listed companies involved in this space.
Hisun’s product and organizational systems are now fully integrated into the global pharmaceutical supply chain. The company’s strategy of acquiring generic drugs is seen as a key pillar for future valuation growth. In the broader context of global generic drug M&A trends, industry value is increasingly influencing stock valuations, shifting away from traditional financial metrics. Shareholding and asset restructuring are becoming essential tools for multinational generic pharmaceutical companies to optimize resource integration. Given these dynamics, Hisun remains a cautiously recommended investment opportunity.
Plant extract is a kind of product that takes plant as raw material, uses appropriate solvent or method. According to the use needs of the final product, through physical and chemical extraction and separation process, directional acquisition and concentration of one or more effective components in plants, without changing the structure of its effective components. The product concept of plant extracts is relatively broad. According to the different components of the extracted plants, they form glycosides, acids, polyphenols, polysaccharides, terpenoids, flavonoids, alkaloids, etc.
Herbal Extracts,Barley Grass Powder,Turmeric Extract,Rose Extract Powder
Xi'an Longze Biotechnology Co., Ltd. , https://www.bestbilberry.com